1. CT-132 is the first FDA-authorized prescription digital therapeutic for episodic migraine prevention.
2. Clinical studies support its ability to reduce monthly migraine days and improve quality of life.
3. CT-132 is intended to complement existing treatment regimens without contraindications.
4. It may support future clinical benefit claims aligned with the FDA's guidance on Prescription Drug Use-Related Software.

Source: Click Therapeutics